Form 8-K - Current report:
SEC Accession No. 0001193805-25-001570
Filing Date
2025-11-13
Accepted
2025-11-13 07:26:52
Documents
14
Period of Report
2025-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 e664954_8k-immunic.htm   iXBRL 8-K 22201
2 e664954_ex99-1.htm EX-99.1 70383
6 GRAPHIC image_001.jpg GRAPHIC 6334
  Complete submission text file 0001193805-25-001570.txt   280201

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE imux-20251113.xsd EX-101.SCH 3002
4 XBRL LABEL FILE imux-20251113_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE imux-20251113_pre.xml EX-101.PRE 22350
16 EXTRACTED XBRL INSTANCE DOCUMENT e664954_8k-immunic_htm.xml XML 3785
Mailing Address 1200 AVENUE OF THE AMERICAS SUITE 200 NEW YORK X1 10036
Business Address 1200 AVENUE OF THE AMERICAS SUITE 200 NEW YORK X1 10036 (332) 255-9818
IMMUNIC, INC. (Filer) CIK: 0001280776 (see all company filings)

EIN.: 562358443 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36201 | Film No.: 251475403
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)